|
| Status |
Public on Apr 17, 2024 |
| Title |
Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Sunitinib resistance creates a major clinical challenge for the treatment of advanced clear cell renal cell carcinoma (ccRCC) and functional and metabolic changes linked to sunitinib resistance are not fully understood. We sought to characterize the molecular and metabolic changes induced by the development of sunitinib resistance in ccRCC by developing and characterizing the transcriptome of two human ccRCC cell lines resistant to sunitinib.
|
| |
|
| Overall design |
Two human advanced renal cell carcinoma cell lines A498 and 786-O were purchased from American Type Culture Collection. Sunitinib (SU11248) malate was purchased from Selleckchem. For the development of sunitinib-resistant cells, parental cells were exposed to increasing concentrations of sunitinib. In brief, the RCC cell lines were treated with varying concentrations of sunitinib (0, 1, 2, 3, 4, 5, 7, 10, 20 and 50 μM). With the passage of time of every 4 days, it has been observed that A498 cells showed stable growth and eventually became confluent at a concentration of 2 µM, while 798-O cells showed stable growth to confluence at a concentration of 4 µM. It can be assumed that cells that grew to confluence had developed stable sunitinib-resistance after a period of 4 months or >20 passages. The cells were constantly in sunitinib containing medium throughout the selection process.
|
| |
|
| Contributor(s) |
Susmita G, Sourbier C, Norris AL |
| Citation(s) |
38263737 |
| Submission date |
Oct 25, 2022 |
| Last update date |
Apr 17, 2024 |
| Contact name |
Alexis L Norris |
| E-mail(s) |
alexis.norris@fda.hhs.gov
|
| Organization name |
US FDA
|
| Street address |
7500 Standish Place
|
| City |
Rockville |
| State/province |
MD |
| ZIP/Postal code |
20855 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (12)
|
| GSM6674914 |
A498 Sunitinib-resistant replicate 1 [42veh1] |
| GSM6674915 |
A498 Sunitinib-resistant replicate 2 [42veh2] |
| GSM6674916 |
A498 Sunitinib-resistant replicate 3 [42veh3] |
| GSM6674917 |
A498 parental replicate 1 [4_veh1] |
| GSM6674918 |
A498 parental replicate 2 [4_veh2] |
| GSM6674919 |
A498 parental replicate 3 [4_veh3] |
| GSM6674920 |
786-O Sunitinib-resistant replicate 1 [74veh1] |
| GSM6674921 |
786-O Sunitinib-resistant replicate 2 [74veh2] |
| GSM6674922 |
786-O Sunitinib-resistant replicate 3 [74veh3] |
| GSM6674923 |
786-O parental replicate 1 [7_veh1] |
| GSM6674924 |
786-O parental replicate 2 [7_veh2] |
| GSM6674925 |
786-O parental replicate 3 [7_veh3] |
|
| Relations |
| BioProject |
PRJNA894090 |
Less...
More...